Nano-X Imaging (NNOX) details legal opinion on $53.9M ATM shares
Rhea-AI Filing Summary
Nano-X Imaging Ltd provides a legal opinion from Meitar Law Offices covering the validity of the remaining $53.9 million of ordinary shares, par value NIS 0.01, that may be issued and sold from time to time under its at-the-market Controlled Equity Sales Agreement with Cantor Fitzgerald and Mizuho Securities.
These potential issuances are made pursuant to Nano-X’s effective shelf registration statement on Form F-3, filed March 13, 2026 and declared effective March 30, 2026, and a July 23, 2026 prospectus supplement. The materials are incorporated by reference into that registration framework and expressly do not themselves constitute an offer to sell shares.
Positive
- None.
Negative
- None.
Key Figures
ATM capacity: $53.9 million
Par value: NIS 0.01 per share
Form F-3 filing date: March 13, 2026
+4 more
7 metrics
ATM capacity
$53.9 million
Remaining ordinary shares that may be issued and sold under the Controlled Equity Sales Agreement
Par value
NIS 0.01 per share
Par value of Nano-X Imaging ordinary shares
Form F-3 filing date
March 13, 2026
Date the Form F-3 shelf registration statement was filed with the SEC
Form F-3 amendment date
March 26, 2026
Date Amendment No. 1 to the Form F-3 was filed
Form F-3 effectiveness date
March 30, 2026
Date the Form F-3 registration statement was declared effective by the SEC
Sales Agreement date
June 7, 2024
Date of the Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. and Mizuho Securities USA LLC
Prospectus Supplement date
July 23, 2026
Date of the prospectus supplement filed under Rule 424(b)(5)
Key Terms
Controlled Equity Sales Agreement, shelf registration statement on Form F-3, prospectus supplement, Rule 424(b)(5)
4 terms
Controlled Equity Sales Agreement financial
"under the Controlled Equity Sales Agreement, dated June 7, 2024, with Cantor and Mizuho"
shelf registration statement on Form F-3 regulatory
"pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-294302)"
prospectus supplement regulatory
"and a prospectus supplement, dated July 23, 2026, filed by the Company"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 424(b)(5) regulatory
"filed by the Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act"
Offering Details
ATM
Offering
Offering Type
ATM
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Nano-X Imaging (NNOX) disclose about its at-the-market offering?
Nano-X Imaging files a legal opinion covering the validity of the remaining $53.9 million of ordinary shares under its at-the-market Controlled Equity Sales Agreement. The opinion supports future share issuances pursuant to an effective Form F-3 shelf registration and a July 23, 2026 prospectus supplement.
Which institutions act as sales agents for Nano-X Imaging (NNOX) under the ATM agreement?
Cantor Fitzgerald & Co. and Mizuho Securities USA LLC serve as sales agents under Nano-X Imaging’s Controlled Equity Sales Agreement. Ordinary shares may be issued and sold through them from time to time under the Form F-3 shelf and July 23, 2026 prospectus supplement.
What role does Meitar Law Offices play in Nano-X Imaging’s (NNOX) ATM program?
Meitar Law Offices, as Israeli legal counsel, issues an opinion on the validity of the ordinary shares that may be issued under Nano-X Imaging’s at-the-market program. This opinion is filed as an exhibit and incorporated by reference into the Form F-3 and prospectus supplement.